3.98  0.06 (1.53%)		12-01 16:00
Open: 3.99 High: 3.99 Volume: 20,993		Pre. Close: 3.92 Low: 3.75 Market Cap: 121(M)

Short term
Mid term
Targets	6-month :	5.18	1-year :	6.05
Resists	First :	4.44	Second :	5.18
Pivot price	3.76
Supports	First :	3.86	Second :	3.5
MAs	MA(5) :	3.81	MA(20) :	3.82
	MA(100) :	4.49	MA(250) :	4.23
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	65.2	D(3) :	47.8
RSI	RSI(14): 55
52-week	High :	6.69	Low :	3

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ XBIT ] has closed below upper band by 9.0%. Bollinger Bands are 33.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.99 - 4.01	4.01 - 4.03
Low:	3.71 - 3.73	3.73 - 3.75
Close:	3.95 - 3.98	3.98 - 4.01

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Sat, 11 Nov 2023
XBiotech (NASDAQ:XBIT) Coverage Initiated by Analysts at ... - Defense World

Sat, 16 Sep 2023
Individual investors account for 50% of XBiotech Inc.'s (NASDAQ ... - Yahoo Finance

Wed, 23 Aug 2023
Biotechs are Accelerating Drug Discovery by Repurposing Platforms ... - Nasdaq

Wed, 11 May 2022
Understanding Small Cap Stocks | Financial Literacy - Investment U

Wed, 02 Feb 2022
J&J to record $610 mln charge related to skin disease drug - Reuters

Wed, 28 Oct 2020
5 Ben Graham Lost Formula Stocks With High Financial Strength - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	30 (M)
Held by Insiders	1.98e+007 (%)
Held by Institutions	35.1 (%)
Shares Short	277 (K)
Shares Short P.Month	0 (K)

EPS	-3.533e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-12 %
Return on Assets (ttm)	361.6 %
Return on Equity (ttm)	-9.7 %
Qtrly Rev. Growth	300000 %
Gross Profit (p.s.)	0
Sales Per Share	-7.12
EBITDA (p.s.)	2.41727e+006
Qtrly Earnings Growth	-0.8 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-18 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.56
Price to Cash Flow	0.75

Dividend	0
Forward Dividend	294470
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.